The adoptive transfer of CAR T cells has demonstrated remarkable success in treating blood-borne tumors. The use of CD19 CARs in leukemia (LAL) and lymphoma (DLBCL) received Breakthrough Therapy Designation by the FDA.
Aurora is pioneering the technology for solid tumors. We are using the next generation of CAR-T comprising of bi-specific CAR-T cells to target established solid Tumor Associated Antigens (“TAA’s”)
|Product||Agent||Indication||Pre-clinical||Phase I/IIa||Phase I(b)//II(a)||Phase II(b)/III||FDA Approval|